FrancophonIA/ELRC3.0 huggingface dataset:
English: Pylobactell is not recommended for use in patients below 18 years of age because there is insufficient information on its effectiveness in this group.
Estonian: Pylobactelli ei soovitata kasutada alla 18-aastastel patsientidel, kuna efektiivsuse andmed ei ole selle rühma kohta piisavad.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pylobactell on 7 May 1998.
Estonian: Euroopa Komisjon andis Pylobactelli müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 7. mail 1998.
English: Finally, 30 minutes later (40 minutes after the test meal), the patient collects a further three breath samples.
Estonian: Ja lõpuks, 30 minuti pärast (40 minutit pärast testeinet) teeb patsient veel kolm hingamistesti.
English: The Committee recommended that Pylobactell be given marketing authorisation.
Estonian: Komitee soovitas anda Pylobactellile müügiloa.
English: The results obtained were compared to see if they agreed.
Estonian: Võrreldi saadud tulemuste omavahelist vastavust.
English: First, the patient takes a ‘test meal' (such as 200 ml of pure undiluted orange juice).
Estonian: Patsiendile antakse kõigepealt testeine (näiteks 200 ml puhast lahjendamata suhkruta apelsinimahla).
English: After a further five minutes, the patient takes the Pylobactell tablet dissolved in water.
Estonian: Veel viie minuti pärast manustab patsient ühe vees lahustatud Pylobactelli tableti.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) PYLOBACTELL EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE PYLOBACTELL Kokkuvõte üldsusele
English: H. pylori produces enzymes called ureases that break down urea into ammonia and carbon dioxide.
Estonian: H. pylori toodab ensüümi ureaasi, mis lagundab uurea ammoniaagiks ja süsinikdioksiidiks.
English: If the patient has eaten a heavy meal then they should fast for six hours before the test.
Estonian: Kui patsient on söönud tugeva eine, peab ta olema enne testi tegemist kuus tundi söömata.
English: The carbon dioxide is then removed from the body in the breath.
Estonian: Süsinikdioksiid väljub seejärel organismist väljahingatava õhuga.
English: To carry out the test, the patient must collect six breath samples, three before taking the Pylobactell tablet and three after taking it.
Estonian: Patsient peab koguma testimiseks kuus hingamisproovi, millest kolm võetakse enne ja kolm pärast Pylobactelli tableti manustamist.
English: Five minutes later, the patient collects three breath samples.
Estonian: Viis minutit hiljem teeb patsient kolm hingamistesti.
English: H. pylori is a bacterium that is a factor in diseases such as dyspepsia (heartburn, bloating and nausea), gastritis (inflammation of the stomach) and peptic ulcer disease (ulcers in the stomach or the duodenum).
Estonian: H. pylori on bakter, mis põhjustab näiteks järgmisi haigusi: düspepsia (kõrvetised, pundumine ja iiveldus), gastriit (maopõletik) ja peptilised (mao või kaksteistsõrmiku) haavandid.
English: The active substance in Pylobactell, 13C-urea, is the natural chemical urea that has been labelled with carbon-13 (13C).
Estonian: Pylobactellis toimeainena sisalduv 13C-uurea on looduslik keemiline aine uurea, mis on märgistatud süsinik-13-ga (13C).
English: Pylobactell was more than 95% sensitive in detecting infection with H. pylori.
Estonian: Pylobactelli tundlikkus H. pylori nakkuse avastamisel oli rohkem kui 95%.
English: Pylobactell should not be used in people who may be hypersensitive (allergic) to 13C-urea or any of the other ingredients in the tablet.
Estonian: Pylobactelli ei tohi kasutada patsiendid, kes võivad olla 13C-uurea või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: If there is an increased level of labelled carbon dioxide in the breath sample after 30 minutes (a positive test), the patient may have H. pylori in the stomach or duodenum.
Estonian: Kui väljahingatava õhu proovis on 30 minuti pärast märgistatud süsinikdioksiidi sisaldus suurenenud (test on positiivne), võib patsiendil olla H. pylori nakkus maos või kaksteistsõrmikus.
English: Pylobactell is a breath test: breath samples are collected in the tubes provided in the kit.
Estonian: Pylobactelli kasutatakse hingamistestiks: komplektis sisalduvatesse tuubidesse kogutakse väljahingatava õhu proove.
English: What is the risk associated with Pylobactell?
Estonian: Mis riskid Pylobactelliga kaasnevad?
English: If there is no increased level of labelled carbon dioxide in the breath, the patient might not have H. pylori in the stomach or duodenum.
Estonian: Kui väljahingatavas õhus märgistatud süsinikdioksiidi sisaldus ei ole suurenenud, ei pruugi patsiendi maos või kaksteistsõrmikus H. pylori nakkust olla.
English: Pylobactell should not be used in patients who have, or may have gastric (stomach) infection, which might interfere with the breath test.
Estonian: Pylobactelli ei tohi kasutada patsiendid, kellel on või võib olla hingamistesti mõjutav maonakkus.
English: Why has Pylobactell been approved?
Estonian: Miks Pylobactell heaks kiideti?
English: What is Pylobactell?
Estonian: Mis on Pylobactell?
English: Other information about Pylobactell:
Estonian: Muu teave Pylobactelli kohta
English: The full EPAR for Pylobactell is available here.
Estonian: Pylobactelli Euroopa avaliku hindamisaruande täisteksti Pylobactelli kohta leiate siit.
English: The patient should fast for four hours before the test so that it is done on an empty stomach.
Estonian: Et testi saaks teha tühja kõhuga, peab patsient olema söömata neli tundi enne testi tegemist.
English: Pylobactell is used to diagnose Helicobacter pylori (H. pylori) infection in the stomach and duodenum (the part of the gut just below the stomach).
Estonian: Pylobactelli kasutatakse mao ja kaksteistsõrmiku (soolestiku osa vahetult mao all) Helicobacter pylori (H. pylori) nakkuse diagnoosimiseks.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Pylobactell's benefits are greater than its risks for the in vivo diagnosis of gastroduodenal H. pylori infection.
Estonian: Inimravimite komitee jõudis otsusele, et Pylobactelli kasulikkus mao ja kaksteistsõrmiku H. pylori nakkuse in vivo diagnoosimisel on suurem kui sellega kaasnevad riskid.
English: The data to support the use of Pylobactell comes from two main studies of the use of antibiotics to treat H. pylori infection, where it was used as a test. A total of 366 patients underwent both a Pylobactell test and a standard biopsy test (where a sample from the stomach is analysed to see if it is infected).
Estonian: Pylobactelli kasutamist toetavad andmed pärinevad kahest põhiuuringust antibiootikumide kasutamise kohta H. pylori nakkuse raviks, kus ravimit kasutati testina.
English: It is available as a kit that includes a white soluble tablet containing 100 mg of the active substance 13C-urea.
Estonian: Pylobactell on diagnostiline test. Seda turustatakse komplektina, mis sisaldab valgeid lahustuvaid tablette, mis sisaldavad toimeainena 100 mg 13C-uuread.
English: What benefit has Pylobactell shown during the studies?
Estonian: Milles seisneb uuringute põhjal Pylobactelli kasulikkus?
English: How does Pylobactell work?
Estonian: Kuidas Pylobactell toimib?
English: What is Pylobactell used for?
Estonian: Milleks Pylobactelli kasutatakse?
English: If the patient has , the 13C-urea contained in the Pylobactell tablet is broken down and the carbon dioxide in the breath also contains 13C.
Estonian: Kui patsiendile manustada Pylobactelli, lagundab H. pylori Pylobactelli tabletis sisalduva 13C-uurea ning väljahingatava õhu süsinikdioksiid sisaldab ka 13C-d. Seda 13C-märgistatud süsinikdioksiidi saab mõõta spetsiaalsetes laboratooriumides, kus kasutatakse mass-spektromeetria meetodit.
English: How has Pylobactell been studied?
Estonian: Kuidas Pylobactelli uuriti?
English: How is Pylobactell used?
Estonian: Kuidas Pylobactelli kasutatakse?
English: Kogenate Bayer is intended for either short-term or long-term use.
Estonian: Kogenate Bayer on ette nähtud kas lühiajaliseks või pikaajaliseks kasutamiseks.
English: The full EPAR for Kogenate Bayer can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Kogenate Bayeri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for Kogenate Bayer on 4 August 2000.
Estonian: Euroopa Komisjon andis Kogenate Bayeri müügiloa, mis kehtib kogu Euroopa Liidus, 4. augustil 2000.
English: Patients or their carers may be able to administer Kogenate Bayer themselves at home once they have been trained appropriately.
Estonian: Patsiendid või nende hooldajad tohivad Kogenate Bayerit kodus ise manustada, kui on saanud asjakohase väljaõppe.
English: Skin- associated hypersensitivity reactions (itching, hives and rash) may occur commonly (in between 1 and 10 patients in 100) but a severe allergic reaction is rare (between 1 and 10 in 10,000 patients).
Estonian: Nahaga seotud ülitundlikkusreaktsioone (sügelus, nõgeslööve ja lööve) võib esineda sageli (1-10 patsiendil 100st), kuid raskeid allergilisi reaktsioone esineb harva (1-10 patsiendil 10 000st).
English: What measures are being taken to ensure the safe and effective use of Kogenate Bayer?
Estonian: Mis meetmed võetakse, et tagada Kogenate Bayeri ohutu ja efektiivne kasutamine?
English: Kogenate Bayer octocog alfa
Estonian: Kogenate Bayer alfaoktokog
English: What is Kogenate Bayer and what is it used for?
Estonian: Mis on Kogenate Bayer ja milleks seda kasutatakse?
English: Because of this, Kogenate Bayer has been compared with Kogenate to show that the two medicines are equivalent.
Estonian: Seetõttu võrreldi Kogenate Bayerit Kogenatega, et tõendada nende kahe ravimi ekvivalentsust.
English: This is a summary of the European public assessment report (EPAR) for Kogenate Bayer.
Estonian: See on ravimi Kogenate Bayer Euroopa avaliku hindamisaruande kokkuvõte.
English: The dose and duration of treatment depend on whether it is used to treat or prevent bleeding or during surgery, as well as on the patient's factor VIII levels, the seriousness of the haemophilia, the extent and location of the bleeding and the patient's condition and bodyweight.
Estonian: Annus ja ravi kestus sõltuvad sellest, kas Kogenate Bayerit kasutatakse verejooksu raviks või profülaktikaks või operatsiooni ajal, samuti patsiendi VIII hüübimisfaktori sisaldusest, hemofiilia raskusastmest, verejooksu ulatusest ja asukohast ning patsiendi seisundist ja kehamassist.
English: Kogenate Bayer given as an injection into a vein has been studied in 66 patients who had previously been treated with recombinant human coagulation factor VIII and 61 children who had not.
Estonian: Veenisüstega manustatavat ravimit Kogenate Bayer uuriti 66 patsiendil, keda oli varem ravitud rekombinantse VIII inimhüübimisfaktoriga, ning 61 lapsel, keda ei olnud varem ravitud.
English: The dose may need to be adjusted if Kogenate Bayer is to be given continuously as an infusion into a vein.
Estonian: Annust võib olla vaja kohandada, kui Kogenate Bayerit manustatakse veeni pidevinfusioonina.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kogenate Bayer have been included in the summary of product characteristics and the package leaflet.
Estonian: Kogenate Bayeri ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Kogenate Bayer is used to correct the factor VIII deficiency by replacing the missing factor VIII, giving temporary control of the bleeding disorder.
Estonian: Kogenate Bayerit kasutatakse VIII hüübimisfaktori vaeguse korrigeerimiseks, asendades puuduva VIII hüübimisfaktori, millega saab verejookse ajutiselt leevendada.
English: The Agency decided that Kogenate Bayer's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Amet otsustas, et Kogenate Bayeri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: In the previously treated patients, overall, 95% of bleeds responded to one or two injections of Kogenate Bayer into a vein.
Estonian: Varem ravitud patsientide verejooksudest reageeris kokku 95% ravimi Kogenate Bayer ühele või kahele veenisüstele.
English: Why is Kogenate Bayer approved?
Estonian: Miks Kogenate Bayer heaks kiideti?
English: For practical information about using Kogenate Bayer, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Kogenate Bayeri kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: It is not intended to provide practical advice on how to use Kogenate Bayer.
Estonian: Hindamisaruandes ei anta ravimi Kogenate Bayer kasutamise praktilisi nõuandeid.
English: The Agency concluded that Kogenate Bayer has been shown to be effective at treating and preventing bleeding in patients with haemophilia A and has an acceptable safety profile.
Estonian: Amet järeldas, et on tõendatud Kogenate Bayeri efektiivsus A-hemofiiliaga patsientide veritsusepisoodide ennetamisel ja ravis ning et ohutusprofiil on vastuvõetav.
English: For more information about treatment with Kogenate Bayer, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Kogenate Bayeriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Kogenate Bayer is similar to another medicine that was previously authorised in the EU called Kogenate, but it is prepared differently so that there are no human-derived proteins in the medicine.
Estonian: Kogenate Bayer sarnaneb Euroopa Liidus heaks kiidetud ravimile Kogenate, kuid seda toodetakse teistmoodi, nii et ravimis ei leidu inimpäritoluga valke.
English: For the full list of all side effects reported with Kogenate Bayer, see the package leaflet.
Estonian: Kogenate Bayeri kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What are the risks associated with Kogenate Bayer?
Estonian: Mis riskid Kogenate Bayeriga kaasnevad?
English: Patients with haemophilia A lack factor VIII, and this causes blood clotting problems, such as bleeding in the joints, muscles and internal organs.
Estonian: A-hemofiiliaga patsientidel on VIII hüübimisfaktori vaegus, mis põhjustab hüübimishäireid, näiteks liigeste, lihaste või siseelundite verejookse.
English: Kogenate Bayer must not be used in people who are known to be hypersensitive (allergic) to human coagulation factor VIII, to mouse or hamster protein, or to any of the other ingredients.
Estonian: Kogenate Bayerit ei tohi kasutada patsiendid, kes on inimese VIII hüübimisfaktori, hiire- või hamstrivalkude või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: How is Kogenate Bayer used?
Estonian: Kuidas Kogenate Bayerit kasutatakse?
English: Other information about Kogenate Bayer
Estonian: Muu teave Kogenate Bayeri kohta
English: It contains the active substance octocog alfa (human coagulation factor VIII).
Estonian: Kogenate Bayer sisaldab toimeainena alfaoktokogi (inimese VIII hüübimisfaktorit).
English: Kogenate Bayer given at high dose has been studied to see whether it is effective in clearing antibodies against factor VIII from the blood (a process known as immune tolerance induction) so that treatment with factor VIII remains effective.
Estonian: Uuriti ka ravimi Kogenate Bayeri suurt annust, et leida, kas see eemaldab verest VIII hüübimisfaktori vastaseid antikehi (immuuntaluvuse tekitamine), et ravi VIII faktoriga püsiks efektiivne.
English: Kogenate Bayer is a medicine used for the treatment and prevention of bleeding in patients of all ages with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII).
Estonian: Kogenate Bayer on ravim, mida kasutatakse A-hemofiiliaga (VIII hüübimisfaktori vaeguse põhjustatud kaasasündinud hüübimishäire) patsientide verejooksude raviks ja profülaktikaks.
English: How does Kogenate Bayer work?
Estonian: Kuidas Kogenate Bayer toimib?
English: The active substance in Kogenate Bayer, octocog alfa (human coagulation factor VIII), is a substance that helps the blood to clot.
Estonian: Kogenate Bayeri toimeaine alfaoktokog (inimese VIII hüübimisfaktor) on vere hüübimist soodustav valk.
English: Kogenate Bayer as a continuous infusion has also been studied in 15 patients with haemophilia A undergoing major surgery.
Estonian: Uuriti ka ravimi Kogenate Bayeri pidevinfusiooni 15 A-hemofiiliaga patsiendil, kellele tehti raske operatsioon.
English: The data provided on immune tolerance induction in patients with inhibitors showed that some patients benefit from the high dosage and the inhibitor could be eliminated, nevertheless the data were not considered sufficient to specifically approve the medicine for this use.
Estonian: Immuuntaluvuse tekitamise andmed VIII hüübimisfaktori inhibiitoritega patsientidel tõendasid, et mõnele patsiendile on suur annus kasulik ja eemaldab inhibiitoreid.
English: There is a risk with factor VIII medicines that some patients will develop inhibitors (antibodies) against factor VIII, causing the medicine to stop working and resulting in a loss of bleeding control.
Estonian: Mõnel VIII hüübimisfaktorit sisaldavaid ravimeid kasutaval patsiendil võivad tekkida VIII hüübimisfaktori vastased inhibiitorid (antikehad), mis peatavad ravimi toime, nii et see ei peata enam verejookse.
English: What benefits of Kogenate Bayer have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Kogenate Bayeri kasulikkus?
English: Kogenate Bayer is available as a powder and solvent that are mixed together to make a solution for injection or infusion (drip) into a vein.
Estonian: Kogenate Bayerit turustatakse veenisüste- või -infusioonilahuse pulbri ja lahustina.
English: Kogenate Bayer can only be obtained with a prescription and treatment should be started by a doctor experienced in the treatment of haemophilia.
Estonian: Ravi peab alustama hemofiilia ravis kogenud arsti järelevalve all.
English: 1 patch + 1 cleansing gel
Estonian: 1 plaaster + 1 puhastusgeel
English: 2 patches + 1 cleansing gel
Estonian: 2 plaastrit + 1 puhastusgeel
English: Strength Pharmaceutical Form
Estonian: Ravimvorm Manustamisviis Pakend
English: The European Commission granted a marketing authorisation valid throughout the European Union for Competact on 28 July 2006.
Estonian: Euroopa Komisjon andis Competacti müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 28. juulil 2006.
English: Other information about Competact
Estonian: Muu teave Competacti kohta
English: A risk management plan has been developed to ensure that Competact is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Competacti võimalikult ohutu kasutamine.
English: The full EPAR for Competact can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Competacti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of Competact?
Estonian: Mis meetmed võetakse, et tagada Competacti ohutu ja efektiivne kasutamine?
English: The usual dose of Competact is one tablet taken twice a day.
Estonian: Competacti tavaline annus on üks tablett kaks korda ööpäevas.
English: Competact contains two active substances which each have a different mode of action.
Estonian: Competact sisaldab kaht toimeainet, mille toimemehhanismid on erinevad.
English: Treatment with Competact should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Estonian: Competacti ravivastus tuleb 3-6 kuu möödudes läbi vaadata ning lõpetada ravi patsientidel, kellele ravi ei ole piisavalt kasulik.
English: Pioglitazone / metformin hydrochloride
Estonian: Competact pioglitasoon / metformiinvesinikkloriid
English: The studies lasted from 4 months to 2 years and involved 1,305 patients who took the combination.
Estonian: Uuringud kestsid 4 kuust 2 aastani ja nendes osales 1305 patsienti, kes võtsid mõlema ravimi tablette.
English: Competact is a medicine that is available as tablets containing two active substances, pioglitazone (15 mg) and metformin hydrochloride (850 mg).
Estonian: Competact on ravim, mida turustatakse tablettidena, mis sisaldavad kaht toimeainet: pioglitasooni (15 mg) ja metformiinvesinikkloriidi (850 mg).
English: In addition, the company that markets Competact will produce educational materials for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting.
Estonian: Lisaks varustab Competacti turustav ettevõte ravimit raviks määravad arstid teabematerjaliga, milles selgitatakse südamepuudulikkuse ja kusepõie vähi võimalikku riski pioglitasooni sisaldavate ravimite kasutamisel, patsientide valikukriteeriume ning vajadust ravi regulaarselt üle vaadata ja lõpetada, kui see ei ole patsientidele enam kasulik.
English: The Committee decided that Competact's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Competacti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Estonian: 2. tüüpi diabeet on haigus, mille korral kõhunäärmes ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini või organism ei suuda insuliini efektiivselt kasutada.
English: Patients changing from metformin only to Competact may need to slowly introduce pioglitazone until a dose of 30 mg per day is reached.
Estonian: Ainult metformiini ravi saanud patsiendid, kellele hakatakse manustama Competacti, võivad vajada aeglast üleminekut pioglitasoonile, kuni saavutatakse 30 mg annus ööpäevas.
English: In all studies, adding pioglitazone 30 mg to metformin led to an improvement in the control of blood glucose, with levels of HbA1c further decreasing by 0.64 to 0.89% compared with the levels on metformin alone.
Estonian: 30 mg pioglitasooni lisamine aitas kõikides uuringutes patsientide vere glükoosisisaldust paremini reguleerida kui üksnes metformiin, vähendades HbA1c-sisaldust veel 0,64-0,89% võrra.
English: The CHMP concluded that the effectiveness of pioglitazone and metformin in type 2 diabetes had been shown, and that Competact simplifies treatment and improves compliance when a combination of the active substances is required.
Estonian: Inimravimite komitee järeldas, et pioglitasooni ja metformiini efektiivsus 2. tüüpi diabeedi ravis on tõendatud ning et Competact lihtsustab ravi ja parandab raviskeemi järgimist, kui tuleb kasutada kahe toimeaine kombinatsiooni.
English: This is a summary of the European public assessment report (EPAR) for Competact.
Estonian: See on ravimi Competact Euroopa avaliku hindamisaruande kokkuvõte.
English: As a result of the action of both active substances, the blood glucose is reduced and this helps to control type 2 diabetes.
Estonian: Mõlema toimeaine toimel vere glükoosisisaldus väheneb ning see aitab 2. tüüpi diabeeti reguleerida.
English: For more information about treatment with Competact, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Competactiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.